KR102010793B1 - 산소 부족 및 공기압 감소에 인한 고산병의 폐 형태의 치료를 위한 약학 조성물 - Google Patents

산소 부족 및 공기압 감소에 인한 고산병의 폐 형태의 치료를 위한 약학 조성물 Download PDF

Info

Publication number
KR102010793B1
KR102010793B1 KR1020157000350A KR20157000350A KR102010793B1 KR 102010793 B1 KR102010793 B1 KR 102010793B1 KR 1020157000350 A KR1020157000350 A KR 1020157000350A KR 20157000350 A KR20157000350 A KR 20157000350A KR 102010793 B1 KR102010793 B1 KR 102010793B1
Authority
KR
South Korea
Prior art keywords
peptide
seq
peptides
amino acid
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157000350A
Other languages
English (en)
Korean (ko)
Other versions
KR20150037815A (ko
Inventor
베르나르 피셔
루돌프 루카스
헨드릭 피셔
Original Assignee
아펩티코 포어슝 운트 엔트빅크룽 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102010793(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아펩티코 포어슝 운트 엔트빅크룽 게엠베하 filed Critical 아펩티코 포어슝 운트 엔트빅크룽 게엠베하
Publication of KR20150037815A publication Critical patent/KR20150037815A/ko
Application granted granted Critical
Publication of KR102010793B1 publication Critical patent/KR102010793B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020157000350A 2012-06-28 2013-06-19 산소 부족 및 공기압 감소에 인한 고산병의 폐 형태의 치료를 위한 약학 조성물 Active KR102010793B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12173983.3A EP2679239A1 (de) 2012-06-28 2012-06-28 Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
EP12173983.3 2012-06-28
PCT/EP2013/062777 WO2014001177A1 (de) 2012-06-28 2013-06-19 Pharmazeutische zusammensetzung zur behandlung der durch sauerstoffarmut und verringerten luftdruck vermittelten pulmonalen form der höhenkrankheit

Publications (2)

Publication Number Publication Date
KR20150037815A KR20150037815A (ko) 2015-04-08
KR102010793B1 true KR102010793B1 (ko) 2019-08-14

Family

ID=48672620

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157000350A Active KR102010793B1 (ko) 2012-06-28 2013-06-19 산소 부족 및 공기압 감소에 인한 고산병의 폐 형태의 치료를 위한 약학 조성물

Country Status (14)

Country Link
US (2) US9802985B2 (enExample)
EP (2) EP2679239A1 (enExample)
JP (1) JP6113277B2 (enExample)
KR (1) KR102010793B1 (enExample)
CN (1) CN104427993B (enExample)
AP (1) AP2014008162A0 (enExample)
AU (1) AU2013283563B2 (enExample)
CA (1) CA2875749C (enExample)
EA (1) EA030384B1 (enExample)
ES (1) ES2602197T3 (enExample)
IN (1) IN2015DN00585A (enExample)
MX (1) MX354302B (enExample)
PE (1) PE20150198A1 (enExample)
WO (1) WO2014001177A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6644695B2 (ja) * 2014-03-04 2020-02-12 アペプティコ フオルシユング ウント アントウィクラング ゲーエムベーハー 肺内炎症の減弱化
US10925924B2 (en) 2014-03-18 2021-02-23 Apeptico Forschung Und Entwicklung Gmbh Dry-powder peptide medicament
WO2017064577A1 (en) 2015-08-25 2017-04-20 Bar-Ilan University Asymmetric electrochemical cell apparatus, and operating methods thereof
WO2018211474A1 (en) 2017-05-19 2018-11-22 Trudell Medical International Positive expiratory pressure device
USD874064S1 (en) 2018-05-18 2020-01-28 Trudell Medical International Mask
USD903097S1 (en) 2018-05-18 2020-11-24 Trudell Medical International Mask
USD893806S1 (en) 2018-11-09 2020-08-18 Trudell Medical Internationl Mask and shroud
WO2021087037A1 (en) * 2019-10-29 2021-05-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Lung-specific targeting-peptide (ltp), compositions, and uses thereof
IL294894A (en) 2020-05-08 2022-09-01 Apeptico Forschung & Entwicklung Gmbh A peptide for the prevention or treatment of covid-19

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009149A1 (en) * 1998-08-14 2000-02-24 Innogenetics N.V. Tnf-derived peptides for use in treating oedema

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
WO1994018325A1 (en) 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
CA2575513C (en) 2004-08-06 2014-09-16 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
WO2010102148A2 (en) * 2009-03-04 2010-09-10 Mannkind Corporation An improved dry powder drug delivery system
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) * 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
AT510585B1 (de) * 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009149A1 (en) * 1998-08-14 2000-02-24 Innogenetics N.V. Tnf-derived peptides for use in treating oedema

Also Published As

Publication number Publication date
PE20150198A1 (es) 2015-02-19
EP2679239A1 (de) 2014-01-01
MX2014015048A (es) 2015-06-05
WO2014001177A1 (de) 2014-01-03
IN2015DN00585A (enExample) 2015-06-26
JP6113277B2 (ja) 2017-04-12
US20190211061A1 (en) 2019-07-11
KR20150037815A (ko) 2015-04-08
EA201500061A1 (ru) 2015-06-30
ES2602197T3 (es) 2017-02-20
MX354302B (es) 2018-02-23
US9802985B2 (en) 2017-10-31
CN104427993A (zh) 2015-03-18
EP2866824A1 (de) 2015-05-06
JP2015526399A (ja) 2015-09-10
AU2013283563A1 (en) 2015-01-15
CA2875749A1 (en) 2014-01-03
AU2013283563B2 (en) 2017-06-08
EA030384B1 (ru) 2018-07-31
CN104427993B (zh) 2017-03-08
EP2866824B1 (de) 2016-08-10
AP2014008162A0 (en) 2014-12-31
US20150225460A1 (en) 2015-08-13
CA2875749C (en) 2019-02-26

Similar Documents

Publication Publication Date Title
KR102010793B1 (ko) 산소 부족 및 공기압 감소에 인한 고산병의 폐 형태의 치료를 위한 약학 조성물
CN112717122A (zh) 包含肽和病毒神经氨酸酶抑制剂的组合物
CA2708134C (en) Cyclic protein free from cysteines
RU2538597C2 (ru) Органические соединения для регуляции векторных ионных каналов
Sun et al. Inhibition of microRNA-155 alleviates neurological dysfunction following transient global ischemia and contribution of neuroinflammation and oxidative stress in the hippocampus
US20070293431A1 (en) Method for improving neurotransmission failure using a novel agent
US20240325496A1 (en) Cxc chemokine agonists and antagonists in covid-19 disease and diagnostic assays
EP1888635B1 (en) Neural regeneration peptides and methods for their use
US8372799B2 (en) Reverse protein
EP4313114B1 (en) Combined treatment of brain injury
CN112368014A (zh) 抗分泌因子在治疗和/或预防急性呼吸衰竭中的用途
US20230173028A1 (en) Application of TFF2 Protein and IFN-k Protein Combination in Treatment of a Novel Coronavirus Infection
HK40043003A (en) Composition comprising a peptide and an inhibitor of viral neuraminidase

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 7